New global test will give result of Coronavirus 'in minutes'
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Sunday
February 05, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SUNDAY, FEBRUARY 05, 2023
New global test will give result of Coronavirus 'in minutes'

Coronavirus chronicle

TBS Report
29 September, 2020, 09:15 am
Last modified: 29 September, 2020, 09:25 am

Related News

  • Covid remains a public health emergency, says WHO
  • Potential China wave is 'wild card' for ending Covid emergency: WHO advisors
  • WHO chief hopes Covid will no longer be emergency next year
  • The Prof Writes: Covid-19 - The one that got away from us
  • Long Covid remains a mystery, though theories are emerging

New global test will give result of Coronavirus 'in minutes'

The quick and easy but high-quality tests will allow mass screening of health workers, who are dying in disproportionate numbers in low income countries

TBS Report
29 September, 2020, 09:15 am
Last modified: 29 September, 2020, 09:25 am
Covid-19 novel coronavirus testing kits are packaged on a production line at the SD Biosensor bio-diagnostic company near Cheongju, South Korea. Photo: Getty Images via The Guardian
Covid-19 novel coronavirus testing kits are packaged on a production line at the SD Biosensor bio-diagnostic company near Cheongju, South Korea. Photo: Getty Images via The Guardian

Tests for Covid-19 which will show results in 15 to 30 minutes are about to be spread across the world.

This will slow the pandemic in poor as well as rich countries and potentially save thousands of lives, reports The Guardian.

In a triumph for a global initiative to get vital drugs and vaccines to fight the virus, 120m rapid antigen tests from two companies will be supplied to low- and middle-income countries for $5 (£3.90) each or even less.

Novel coronavirus “happened naturally”: WHO chief

The tests, which look like a pregnancy test, with two blue lines displayed for positive, are read by a health worker. One test has received emergency approval from the World Health Organization (WHO) and the other is expected to get it shortly.

The quick and easy but high-quality tests will allow mass screening of health workers, who are dying in disproportionate numbers in low income countries.

Wealthy countries that have signed up to the Access to Covid tools initiative (ACT accelerator), as the UK has, will also be able to order the tests. The initiative was launched in March by the WHO, the European commission, the Gates Foundation and the French government.

In return for a volume guarantee from the Gates Foundation, the companies are making 20% of their production available to low- and middle-income countries and 80% to the rest. Germany has already ordered 20m tests and France and Switzerland are following suit.

The UK government is keen to get rapid virus tests, which were central to the "moonshot" proposals leaked recently, but it is not clear if they intend to buy these tests. It has invested in British-made saliva tests as well as rapid antigen tests, both of which take about 90 minutes. Saliva tests are being trialled in Salford and Southampton, while DnaNudge, which uses a swab read by a Nudgebox, is in use in some NHS hospitals.

But the WHO-approved rapid antigen tests are faster and easier, as well as cheaper, and could be used for screening in schools, universities and workplaces. Countries that can afford it could screen more generally. While the tests will not pick up all cases, they could allow many infectious people to be identified before they have symptoms and go into quarantine.

One of the tests, from the South Korean company SD BioSensor, has just been given emergency approval by the WHO, while the other, from the US company Abbott, is expected to get it shortly for a test it manufactures in South Korea.

Catharina Boehme, CEO of the non-profit Foundation for Innovative New Diagnostics (Find), a key player in the initiative, said they had put in bulk orders for the tests quickly so that low- and middle-income countries would not lose out in the global scramble for rapid tests, as they did when the PCR tests came out. "We see the pressure of supply building rapidly. That's why we need this volume guarantee. We needed to secure volumes for low- and middle-income countries, before all the other countries place their orders and the poor populations again lose out.

"For us the message is about unprecedented collaboration. We are really able to show what can be achieved when the world and leading global health partners come together with a shared priority."

Also in the partnership that has secured the deal are the Africa Centres for Disease Control and Prevention, the Clinton Health Access Initiative, the Global Fund and Unitaid.

Peter Sands, executive director of the Global Fund, said: "This is the ACT-Accelerator in action. It is proof that by working together at a massive global scale, we can develop and deploy a vital new tool to help contain and fight the pandemic. This is not just a new test – it's the money and the deployment plan to get it to where it's needed, fast. This is the power of global collaboration."

The companies claim their tests are about 97% accurate, but that is in optimal conditions. Find puts their sensitivity between 80% and 90% in real-world conditions. That would pick up most infections. There is relatively little testing in most low- and middle-income countries at present. While North America tests 395 people per 100,000 population daily and Europe tests 243, Africa tests fewer than 16 – and most of those are in Morocco, Kenya and Senegal.

There are rapid antigen tests available for sale online, but these are the first to meet the WHO's specifications and some tests have fallen short. Spain had to send back two batches of rapid tests it bought from unlicensed companies in China in March, because they were said to be faulty.

The ACT accelerator initiative is also working on bulk-buying and distributing drugs to treat Covid-19 around the world – and will share its global portfolio of vaccines when one of them is proved to work.

Top News / World+Biz

Coronavirus / test

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • ICB to withdraw Padma Bank investment as return eludes
    ICB to withdraw Padma Bank investment as return eludes
  • Some tough tasks on the plate for Bangladesh Bank!
    Some tough tasks on the plate for Bangladesh Bank!
  • Influentials thwart Bangladesh's reform attempts: Economists
    Influentials thwart Bangladesh's reform attempts: Economists

MOST VIEWED

  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong says 'hello' to woo back visitors after Covid
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs

Related News

  • Covid remains a public health emergency, says WHO
  • Potential China wave is 'wild card' for ending Covid emergency: WHO advisors
  • WHO chief hopes Covid will no longer be emergency next year
  • The Prof Writes: Covid-19 - The one that got away from us
  • Long Covid remains a mystery, though theories are emerging

Features

Sketch: TBS

Say 'Salud' before your salad main course

15h | Food
Coots running. Photo: Enam Ul Haque

Cute Coot of Baikka Beel: 'And yet he was as bald as a coot'

10h | Panorama
With only one government run specialised cancer hospital in the capital — the National Institute Of Cancer Research and Hospital (NICRH) in Mohakhali — patients have no option but to resort to private hospitals. Photo: Noor A Alam.

Cancer care: Medical treatment and beyond

16h | Panorama
Andy Mukherjee. Sketch: TBS

What makes India's billionaires' support special for Adani

1d | Panorama

More Videos from TBS

Prioritise medical equipment, raw material imports over luxury items

Prioritise medical equipment, raw material imports over luxury items

7h | TBS Round Table
Adani row rocks India’s parliament

Adani row rocks India’s parliament

6h | TBS World
Concord launches new plant to produce environment friendly bricks

Concord launches new plant to produce environment friendly bricks

12h | TBS Stories
How Asif Khan would invest his fresh funds right now

How Asif Khan would invest his fresh funds right now

13h | TBS Markets

Most Read

1
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

2
Photo: Collected
Energy

8 Ctg power plants out of production

3
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

4
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

5
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

6
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net